Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 55

1.

Multi-institutional analysis of stereotactic body radiation therapy for operable early-stage non-small cell lung carcinoma.

Kann BH, Verma V, Stahl JM, Ross R, Dosoretz AP, Shafman TD, Gross CP, Park HS, Yu JB, Decker RH.

Radiother Oncol. 2019 May;134:44-49. doi: 10.1016/j.radonc.2019.01.027. Epub 2019 Feb 1.

PMID:
31005223
2.

Stereotactic body radiotherapy with adjuvant systemic therapy for early-stage non-small cell lung carcinoma: A multi-institutional analysis.

Kann BH, Miccio JA, Stahl JM, Ross R, Verma V, Dosoretz AP, Park HS, Shafman TD, Gross CP, Yu JB, Decker RH.

Radiother Oncol. 2019 Mar;132:188-196. doi: 10.1016/j.radonc.2018.10.017. Epub 2018 Oct 31.

PMID:
30391106
3.

Radiation dose and cardiac risk in breast cancer treatment: An analysis of modern radiation therapy including community settings.

Hong JC, Rahimy E, Gross CP, Shafman T, Hu X, Yu JB, Ross R, Finkelstein SE, Dosoretz A, Park HS, Soulos PR, Evans SB.

Pract Radiat Oncol. 2018 May - Jun;8(3):e79-e86. doi: 10.1016/j.prro.2017.07.005. Epub 2017 Jul 20.

PMID:
28888675
4.

Increased Number of Beam Angles Is Associated With Higher Cardiac Dose in Adjuvant Fixed Gantry Intensity Modulated Radiation Therapy of Left-Sided Breast Cancer.

Rahimy E, Hong JC, Gross CP, Hu X, Soulos PR, Shafman T, Connor HJ, Ross R, Yu JB, Dosoretz A, Evans SB.

Int J Radiat Oncol Biol Phys. 2017 Dec 1;99(5):1137-1145. doi: 10.1016/j.ijrobp.2017.06.2451. Epub 2017 Jun 27.

PMID:
28864402
5.

Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.

Johnson SB, Soulos PR, Shafman TD, Mantz CA, Dosoretz AP, Ross R, Finkelstein SE, Collins SP, Suy S, Brower JV, Ritter MA, King CR, Kupelian PA, Horwitz EM, Pollack A, Abramowitz MC, Hallman MA, Faria S, Gross CP, Yu JB.

Radiother Oncol. 2016 Nov;121(2):294-298. doi: 10.1016/j.radonc.2016.10.013. Epub 2016 Nov 24.

PMID:
27890426
6.

The Effect of Biologically Effective Dose and Radiation Treatment Schedule on Overall Survival in Stage I Non-Small Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.

Stahl JM, Ross R, Harder EM, Mancini BR, Soulos PR, Finkelstein SE, Shafman TD, Dosoretz AP, Evans SB, Husain ZA, Yu JB, Gross CP, Decker RH.

Int J Radiat Oncol Biol Phys. 2016 Dec 1;96(5):1011-1020. doi: 10.1016/j.ijrobp.2016.08.033. Epub 2016 Aug 31.

PMID:
27869080
7.

The American Society for Radiation Oncology's 2015 Core Physics Curriculum for Radiation Oncology Residents.

Burmeister J, Chen Z, Chetty IJ, Dieterich S, Doemer A, Dominello MM, Howell RM, McDermott P, Nalichowski A, Prisciandaro J, Ritter T, Smith C, Schreiber E, Shafman T, Sutlief S, Xiao Y.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1298-303. doi: 10.1016/j.ijrobp.2016.03.012. Epub 2016 Mar 19.

PMID:
27354135
8.

Current status of immunotherapy and gene therapy for high-grade gliomas.

Marsh JC, Goldfarb J, Shafman TD, Diaz AZ.

Cancer Control. 2013 Jan;20(1):43-8. Review.

PMID:
23302906
9.

The utility of non-axial treatment beam orientations for lower lobe lung cancers.

Quaranta BP, Das SK, Shafman TD, Light KL, Marks LB.

J Appl Clin Med Phys. 2010 Jan 28;11(1):3010.

10.

Dose-dependent effects of radiation therapy on cerebral blood flow, metabolism, and neurocognitive dysfunction.

Hahn CA, Zhou SM, Raynor R, Tisch A, Light K, Shafman T, Wong T, Kirkpatrick J, Turkington T, Hollis D, Marks LB.

Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1082-7. doi: 10.1016/j.ijrobp.2008.05.061. Epub 2008 Aug 26.

PMID:
18755558
11.

A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.

Garst J, Herndon JE 2nd, Shafman T, Campagna L, Blackwell S, Padilla K, Bjurstrom T, Andrews C, Maravich-May D, Anderson E, Crawford J.

Clin Drug Investig. 2006;26(5):257-66.

PMID:
17163259
12.

Assessing the ability of the antiangiogenic and anticytokine agent thalidomide to modulate radiation-induced lung injury.

Anscher MS, Garst J, Marks LB, Larrier N, Dunphy F, Herndon JE 2nd, Clough R, Marino C, Vujaskovic Z, Zhou S, Dewhirst MW, Shafman TD, Crawford J.

Int J Radiat Oncol Biol Phys. 2006 Oct 1;66(2):477-82. Epub 2006 Aug 14.

PMID:
16904841
13.

Combination chemotherapy and radiation therapy for upper aerodigestive tract cancers.

Shafman TD.

Med Health R I. 2006 Feb;89(2):55-8. Review. No abstract available.

PMID:
16583662
14.

The impact of pre-radiotherapy surgery on radiation-induced lung injury.

Kocak Z, Yu X, Zhou SM, D'Amico TA, Hollis D, Kahn D, Tisch A, Shafman TD, Marks LB.

Clin Oncol (R Coll Radiol). 2005 Jun;17(4):210-6.

PMID:
15999420
15.

"Anatomically-correct" dosimetric parameters may be better predictors for esophageal toxicity than are traditional CT-based metrics.

Kahn D, Zhou S, Ahn SJ, Hollis D, Yu X, D'Amico TA, Shafman TD, Marks LB.

Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):645-51.

PMID:
15936540
16.

Challenges in defining radiation pneumonitis in patients with lung cancer.

Kocak Z, Evans ES, Zhou SM, Miller KL, Folz RJ, Shafman TD, Marks LB.

Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):635-8.

PMID:
15936538
17.

Dosimetric and clinical predictors for radiation-induced esophageal injury.

Ahn SJ, Kahn D, Zhou S, Yu X, Hollis D, Shafman TD, Marks LB.

Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):335-47. Review.

PMID:
15667951
18.

Bronchial stenosis: an underreported complication of high-dose external beam radiotherapy for lung cancer?

Miller KL, Shafman TD, Anscher MS, Zhou SM, Clough RW, Garst JL, Crawford J, Rosenman J, Socinski MA, Blackstock W, Sibley GS, Marks LB.

Int J Radiat Oncol Biol Phys. 2005 Jan 1;61(1):64-9.

PMID:
15629595
19.

A practical approach to pulmonary risk assessment in the radiotherapy of lung cancer.

Miller KL, Shafman TD, Marks LB.

Semin Radiat Oncol. 2004 Oct;14(4):298-307. Review.

PMID:
15558504
20.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: report of a prospective phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Marks LB, Garst J, Socinski MA, Sibley G, Blackstock AW, Herndon JE, Zhou S, Shafman T, Tisch A, Clough R, Yu X, Turrisi A, Anscher M, Crawford J, Rosenman J; Carolina Conformal Therapy Consortium.

J Clin Oncol. 2004 Nov 1;22(21):4329-40.

PMID:
15514374
21.

Risk of long-term complications after TFG-beta1-guided very-high-dose thoracic radiotherapy.

Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE, Garst J, Crawford J, Jirtle RL.

Int J Radiat Oncol Biol Phys. 2003 Jul 15;56(4):988-95.

PMID:
12829134
22.

Long-term changes in pulmonary function tests after definitive radiotherapy for lung cancer.

Miller KL, Zhou SM, Barrier RC Jr, Shafman T, Folz RJ, Clough RW, Marks LB.

Int J Radiat Oncol Biol Phys. 2003 Jul 1;56(3):611-5.

PMID:
12788165
23.

Routine use of approximately 60 Gy once-daily thoracic irradiation for patients with limited-stage small-cell lung cancer.

Miller KL, Marks LB, Sibley GS, Clough RW, Garst JL, Crawford J, Shafman TD.

Int J Radiat Oncol Biol Phys. 2003 Jun 1;56(2):355-9.

PMID:
12738309
24.

Optimization of a 90Sr/90Y radiation source train stepping for intravascular brachytherapy.

Miften MM, Das SK, Shafman TD, Marks LB.

Med Phys. 2002 Dec;29(12):2891-6.

PMID:
12512724
25.

Receiver operating characteristic curves to assess predictors of radiation-induced symptomatic lung injury.

Lind PA, Marks LB, Hollis D, Fan M, Zhou SM, Munley MT, Shafman TD, Jaszczak RJ, Coleman RE.

Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):340-7.

PMID:
12243806
26.

Phase II trial of murine (131)I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas.

Reardon DA, Akabani G, Coleman RE, Friedman AH, Friedman HS, Herndon JE 2nd, Cokgor I, McLendon RE, Pegram CN, Provenzale JM, Quinn JA, Rich JN, Regalado LV, Sampson JH, Shafman TD, Wikstrand CJ, Wong TZ, Zhao XG, Zalutsky MR, Bigner DD.

J Clin Oncol. 2002 Mar 1;20(5):1389-97.

PMID:
11870184
27.

The time course of radiation therapy-induced reductions in regional perfusion: a prospective study with >5 years of follow-up.

Woel RT, Munley MT, Hollis D, Fan M, Bentel G, Anscher MS, Shafman T, Coleman RE, Jaszczak RJ, Marks LB.

Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):58-67.

PMID:
11777622
28.

Clear cell pleomorphic xanthoastrocytoma: case report.

Primavera J, Nikas DC, Zamani AA, Shafman T, Alexander E 3rd, De Girolami U, Louis DN.

Acta Neuropathol. 2001 Oct;102(4):404-8.

PMID:
11603818
29.

Radiation-induced pulmonary toxicity: a dose-volume histogram analysis in 201 patients with lung cancer.

Hernando ML, Marks LB, Bentel GC, Zhou SM, Hollis D, Das SK, Fan M, Munley MT, Shafman TD, Anscher MS, Lind PA.

Int J Radiat Oncol Biol Phys. 2001 Nov 1;51(3):650-9.

PMID:
11597805
30.

Relating radiation-induced regional lung injury to changes in pulmonary function tests.

Fan M, Marks LB, Lind P, Hollis D, Woel RT, Bentel GG, Anscher MS, Shafman TD, Coleman RE, Jaszczak RJ, Munley MT.

Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):311-7.

PMID:
11567804
31.

Using plasma transforming growth factor beta-1 during radiotherapy to select patients for dose escalation.

Anscher MS, Marks LB, Shafman TD, Clough R, Huang H, Tisch A, Munley M, Herndon JE 2nd, Garst J, Crawford J, Jirtle RL.

J Clin Oncol. 2001 Sep 1;19(17):3758-65.

PMID:
11533099
32.

Carboplatin/paclitaxel or carboplatin/vinorelbine followed by accelerated hyperfractionated conformal radiation therapy: a preliminary report of a phase I dose escalation trial from the Carolina Conformal Therapy Consortium.

Socinski MA, Marks LB, Garst J, Sibley GS, Blackstock W, Turrisi A, Herndon J, Zhou S, Anscher M, Crawford J, Shafman T, Rosenman J.

Oncologist. 2001;6 Suppl 1:20-4.

33.

Systemic metastasis in glioblastoma may represent the emergence of neoplastic subclones.

Park CC, Hartmann C, Folkerth R, Loeffler JS, Wen PY, Fine HA, Black PM, Shafman T, Louis DN.

J Neuropathol Exp Neurol. 2000 Dec;59(12):1044-50. Review.

PMID:
11138924
34.

Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.

Cokgor I, Akabani G, Kuan CT, Friedman HS, Friedman AH, Coleman RE, McLendon RE, Bigner SH, Zhao XG, Garcia-Turner AM, Pegram CN, Wikstrand CJ, Shafman TD, Herndon JE 2nd, Provenzale JM, Zalutsky MR, Bigner DD.

J Clin Oncol. 2000 Nov 15;18(22):3862-72.

PMID:
11078500
35.

Prevalence of germline truncating mutations in ATM in women with a second breast cancer after radiation therapy for a contralateral tumor.

Shafman TD, Levitz S, Nixon AJ, Gibans LA, Nichols KE, Bell DW, Ishioka C, Isselbacher KJ, Gelman R, Garber J, Harris JR, Haber DA.

Genes Chromosomes Cancer. 2000 Feb;27(2):124-9.

PMID:
10612799
36.

Heterozygous germline ATM mutations do not contribute to radiation-associated malignancies after Hodgkin's disease.

Nichols KE, Levitz S, Shannon KE, Wahrer DC, Bell DW, Chang G, Hegde S, Neuberg D, Shafman T, Tarbell NJ, Mauch P, Ishioka C, Haber DA, Diller L.

J Clin Oncol. 1999 Apr;17(4):1259.

PMID:
10561187
37.

Novel radiation technologies for malignant gliomas.

Shafman TD, Loeffler JS.

Curr Opin Oncol. 1999 May;11(3):147-51. Review.

PMID:
10328586
38.

Interaction between ATM protein and c-Abl in response to DNA damage.

Shafman T, Khanna KK, Kedar P, Spring K, Kozlov S, Yen T, Hobson K, Gatei M, Zhang N, Watters D, Egerton M, Shiloh Y, Kharbanda S, Kufe D, Lavin MF.

Nature. 1997 May 29;387(6632):520-3.

PMID:
9168117
39.

The Large-Cell Lymphomas.

Shafman TD, Mauch PM.

Semin Radiat Oncol. 1995 Oct;5(4):267-280.

PMID:
10717151
40.

Activation of the c-Abl tyrosine kinase in the stress response to DNA-damaging agents.

Kharbanda S, Ren R, Pandey P, Shafman TD, Feller SM, Weichselbaum RR, Kufe DW.

Nature. 1995 Aug 31;376(6543):785-8.

PMID:
7651539
41.

Ionizing radiation stimulates a Grb2-mediated association of the stress-activated protein kinase with phosphatidylinositol 3-kinase.

Kharbanda S, Saleem A, Shafman T, Emoto Y, Taneja N, Rubin E, Weichselbaum R, Woodgett J, Avruch J, Kyriakis J, et al.

J Biol Chem. 1995 Aug 11;270(32):18871-4.

42.

Defective induction of stress-activated protein kinase activity in ataxia-telangiectasia cells exposed to ionizing radiation.

Shafman TD, Saleem A, Kyriakis J, Weichselbaum R, Kharbanda S, Kufe DW.

Cancer Res. 1995 Aug 1;55(15):3242-5.

43.

Activation of the pp90rsk and mitogen-activated serine/threonine protein kinases by ionizing radiation.

Kharbanda S, Saleem A, Shafman T, Emoto Y, Weichselbaum R, Kufe D.

Proc Natl Acad Sci U S A. 1994 Jun 7;91(12):5416-20.

44.

Coinduction of c-jun gene expression and internucleosomal DNA fragmentation by ionizing radiation.

Manome Y, Datta R, Taneja N, Shafman T, Bump E, Hass R, Weichselbaum R, Kufe D.

Biochemistry. 1993 Oct 12;32(40):10607-13.

PMID:
8399205
46.

Modulation of cyclic AMP levels and differentiation by adenosine analogs in mouse erythroleukemia cells.

Sherman ML, Shafman TD, Kufe DW.

J Cell Physiol. 1988 Mar;134(3):429-36.

PMID:
2450878
47.

Selective inhibition of spermidine biosynthesis and differentiation by S-adenosyl-1,8-diamino-3-thiooctane in murine erythroleukemia cells.

Sherman ML, Shafman TD, Coward JK, Kufe DW.

Biochem Pharmacol. 1986 Aug 1;35(15):2633-6. No abstract available.

PMID:
2427085
48.

Effects of ornithine decarboxylase inhibition on c-myc expression during murine erythroleukemia cell proliferation and differentiation.

Watanabe T, Sherman M, Shafman T, Iwata T, Kufe D.

J Cell Physiol. 1986 Jun;127(3):480-4.

PMID:
3458709
49.

Inhibitory effects of theophylline and dibutyryl cAMP on murine erythroleukemia cell differentiation.

Sherman ML, Shafman TD, Kufe DW.

Biochem Biophys Res Commun. 1986 Jan 29;134(2):845-51.

PMID:
3004466
50.

Inhibition of murine erythroleukemia cell differentiation by 3-deazaadenosine.

Sherman ML, Shafman TD, Spriggs DR, Kufe DW.

Cancer Res. 1985 Nov;45(11 Pt 2):5830-4.

Supplemental Content

Loading ...
Support Center